The lower the testosterone level achieved in men undergoing androgen deprivation therapy (ADT) for advanced prostate cancer, the better their chances of survival, an Italian study found.

ORLANDO—Serum cholesterol levels may have a role in prostate biology, according to a study.

Parenteral estrogen therapy with high-dose polyestradiol phosphate (PEP, Estradurin) has anticancer efficacy similar to that of combined androgen deprivation (CAD) in patients with metastatic prostate cancer, researchers report.

CHICAGO—Sagopilone, the first in a new class of microtubule stabilizer drugs, may be effective as part of first-line treatment for men with metastatic androgen-independent prostate cancer (AIPC), researchers say.

The prostate cancer gene 3 (PCA3) urine test is superior to percent-free PSA in predicting prostate biopsy outcome, data show.

CONTRARY TO original findings from the Prostate Cancer Prevention Trial (PCPT), finasteride does not increase the risk of high-grade prostate cancer, according to a new analysis.

IRIS International, Inc., of Chatsworth, Calif., after extensive consultation with the FDA, plans to resubmit its 510(k) application for the company's NADiA PSA ultrasensitive diagnostic test with a prognostic claim for identifying post-prostatectomy patients at low risk of prostate cancer recurrence.

High-grade tumors are more likely to be found in smaller prostates, according to researchers in Spain.

MEN WITH localized prostate cancer recurrence following external beam radiotherapy (EBRT) may benefit from salvage therapy with high-intensity focused ultrasound (HIFU), researchers reported in BJU International (2008; online ahead of print).

Statin use by obese men may increase their risk of prostate cancer, according to study findings published in the American Journal of Epidemiology (2008;168:250-260).